Lumicell
Lumicell illuminates cancer and other diseased tissues at the molecular level, enabling physicians to take action in real-time during surgeries to improve patient outcomes.
Insight Through Illumination
Cancer incidence in the US is increasing and is expected to cross 2 Million patients in 2024. There are multiple treatments for cancers with surgery as a predominant treatment. Lumicell recognizes the challenges surgeons face in finding and removing cancerous tissue while conserving as much healthy tissue as possible. That’s why they are committed to pioneering new technologies to help surgeons make more informed decisions in real-time.
Lumicell is revolutionizing cancer surgery with its innovative LumiSystem™, the first FDA-approved fluorescence-guided drug-device combination that enables surgeons to detect residual breast cancer in real-time during lumpectomy. Consisting of the LUMISIGHT™ optical imaging agent and the Lumicell Direct Visualization System (DVS), this breakthrough technology has demonstrated 84% diagnostic accuracy and has helped identify remaining cancer in approximately 7–10% of patients who otherwise might have required additional surgery, thereby significantly improving surgical precision and reducing repeat procedures. Aiming to enhance surgical outcomes and patient care, Lumicell’s portable, intraoperative fluorescence imaging system is now commercially available in the U.S. and is being actively evaluated across additional cancer types—including gastrointestinal and esophageal cancers—spurred by new feasibility trial results and an NIH SBIR grant. Guided by visionary founders—including renowned MIT researchers and a recognized Nobel laureate—Lumicell blends cutting-edge optics, molecular imaging, and clinical expertise to empower surgeons with clearer visualization in the OR, ultimately advancing oncologic care and reducing healthcare costs.
In the News
Lumicell Announces U.S. Launch and First Commercial Use of LumiSystem™
Lumicell has announced the commercial launch of LumiSystem™, the first FDA-approved fluorescence-guided imaging technology for breast cancer that enables real-time detection and removal of residual cancer during lumpectomy, helping improve surgical outcomes and reduce the need for second surgeries.
Starting October 1, 2024, Medicare will reimburse for LUMISIGHT™ under a new pass-through payment, expanding access to Lumicell’s FDA-approved imaging agent that helps detect residual breast cancer during surgery.
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer
The FDA has approved Lumicell’s LumiSystem—combining LUMISIGHT™ and Lumicell™ DVS—which enables real-time, fluorescence-guided detection of residual breast cancer during lumpectomy with 84% diagnostic accuracy, helping reduce the need for second surgeries and marking a major advancement in intraoperative cancer care.